Document is current
Any future updates will be listed below
-
Authors
Motta, Sarah E.
Fioretta, Emanuela S.
Lintas, Valentina
Dijkman, Petra E.
Hilbe, Monika
Frese, Laura
Cesarovic, Nikola
Loerakker, Sandra
Baaijens, Frank P. T.
Falk, Volkmar
Hoerstrup, Simon P.
Emmert, Maximilian Y.
-
Funding
Funding for this research was provided by:
University of Zurich Forschnugskredit (FK-14-031)
Swiss National Science Foundation (PZ00P3_180138)
European Union’s Seventh Framework Program (242008)
- License Information
-
More Information
Article History
Received: 20 May 2020
Accepted: 15 October 2020
First Online: 16 November 2020
Competing interests
: V. Falk has disclosed relevant financial activities outside the submitted work with the following commercial entities: Medtronic GmbH, Boston Scientific and Edwards Lifesciences in relation to educational grants (including travel support) fees for lectures and speeches, fees for professional consultation and research and study funds. F.P.T. Baaijens and S.P. Hoerstrup are shareholders at Xeltis BV and LifeMatrix AG. M.Y. Emmert is a shareholder at LifeMatrix AG. S. Loerakker, F.P.T. Baaijens, and S.P. Hoerstrup are inventors on patent “Controlling TEHV geometry by using predefined inserts during culture” (WO2015044190 A1) held by Eindhoven University of Technology. This patent covers how the shape of the heart valves can be controlled and maintained during the in vitro culture phase. The authors declare no competing interests.
